NORD Honors 2026 Rare Disease Innovators Amid 95% Treatment Gap — National Organization for Rare Disorders, Inc.

Event summary

NORD recognized 18 honorees across biopharma, research, and advocacy for advancing rare disease treatments.
Six industry innovators celebrated for FDA-approved therapies addressing critical unmet needs.
95% of over 10,000 known rare diseases still lack approved treatments.
Awards presented at NORD Breakthrough Summit on October 26-27, 2026 in Washington, D.C.
NORD partners with 360 disease-specific organizations and 49 Rare Disease Centers of Excellence.

The big picture

NORD's 2026 Rare Impact Awards highlight critical progress in rare disease treatment amid a vast unmet need. The recognition of both industry and nonprofit innovators underscores the growing collaboration required to address the 95% of rare diseases lacking therapies. This event comes as biopharma increasingly focuses on niche indications, with FDA approvals serving as key validation points for investment.

What we're watching

Therapeutic Breakthroughs: How the pace of FDA approvals for rare disease treatments will impact biopharma investment strategies.
Nonprofit Innovation: Whether nonprofit-led research can sustain momentum in addressing the 95% treatment gap.
Policy Advocacy: The extent to which legislative changes will accelerate rare disease research and treatment access.